Baricitinib for treating moderate to severe atopic dermatitis in children and young people aged 2 to 17 [TS ID 10639]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for children with severe atopic dermatitis [TS ID 10434]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC